The use of a KATP channel activator which is capable of penetrating the DVC has the potential to recapitulate the effects of leptin, insulin and α-MSH, with the likely result being reductions in hyperinsulinemia, reductions in hepatic gluconeogenesis, reductions in appetite and improved satiety (Figure 1). Here, STAMBP is linked to hyperinsulinism.